Article

Use of sequence variation in three highly variable regions of the mitochondrial DNA for the discrimination of allogeneic platelets.

Medical Biology Division, University of Groningen, the Netherlands.
Transfusion (Impact Factor: 3.53). 05/2006; 46(4):554-61. DOI: 10.1111/j.1537-2995.2006.00775.x
Source: PubMed

ABSTRACT Human mitochondrial DNA (mtDNA) polymorphisms can be used to detect allogeneic transfused platelets. To increase the number of informative polymorphisms we investigated three hypervariable regions (HVR1, HVR2, and HVR3) within the displacement loop (D-loop) region of the mtDNA.
mtDNA was obtained from 119 unrelated blood donors. Forward and reverse primers were designed and conditions optimized to amplify and sequence the template mtDNA by dye terminator cycle sequencing.
We established a sequencing protocol for all three HVRs of the mtDNA. Polymorphic sites were found in all three regions: 66 in HVR1, 44 in HVR2, and 18 in HVR3. Combining the sequence information of HVR1, -2, and -3 resulted in 105 different genotypes of which 95 were unique. We were able to discriminate between two randomly chosen individuals with a random match probability of 1.2 percent.
The D-loop region of mtDNA contains a wealth of informative molecular markers for chimerism and survival studies after transfusions of cellular blood components.

0 Bookmarks
 · 
84 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The measurement of recovery and survival of platelets is an important decisive factor when 'new' platelet products have been developed. Recovery and survival measurements are mostly performed with radioactive-labeled platelets in healthy volunteers. This approach is required by the FDA for acceptance of platelet products that differ substantially in production or storage conditions from standard methods. However, due to regulatory obstacles, such radiolabeling studies are only carried out in designated institutes. Many countries do not require radioactive labeling studies in volunteers prior to accepting new products, and rather rely on surrogate tests. Also, the European guide to the preparation of blood components does not require this step. This paper reviews alternative, non-radioactive methods, which includes biotinylation of platelets, and discrimination of transfused platelets based on HLA discrepancy. The benefits and disadvantages of these methods will be discussed.
    Transfusion and Apheresis Science 11/2009; 42(1):53-61. · 1.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Platelets play a dominant role in the pathogenesis of bleeding disorders and cardiovascular pathology (e.g., myocardial infarction). Nonradioactive labeling of platelets may offer several clinical applications, ranging from survival studies of transfused platelet concentrates to studies on the pathogenesis of stroke. We used ferucarbotran superparamagnetic nanoparticles (NPs) for cell labeling. Platelets incorporated these NPs by endocytosis (without linkers or binding agents). Flow cytometry using FITC-conjugated magnetic NPs showed ex vivo labeling of about 98% of platelets; NPs were predominantly located inside the platelet granules as confirmed by fluorescence microscopy and transmission electron microscopy. Iron concentrations of 2 pg per platelet were reached as determined by atomic absorption spectroscopy. This will enable sensitive ex vivo determination of transfused labeled platelets, allowing survival studies. In vitro, labeled platelets gave a clear signal by 7 Tesla magnetic resonance tomography. Magnetic labeling of platelets may offer a new tool for diagnosis and research in transfusion medicine and cardiovascular medicine. FROM THE CLINICAL EDITOR: In this study a platelet labeling method is discussed and described for in vivo and ex vivo applications, using a binder or linker free fluorescent superparamagnetic iron nanoparticle system. Magnetic labeling of platelets may offer a new tool for diagnosis and research in transfusion medicine and cardiovascular medicine.
    Nanomedicine: nanotechnology, biology, and medicine 10/2011; 8(5):537-44. · 6.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The presence of microchimerism in peripheral blood of solid organ transplant recipients has been postulated to be beneficial for allograft acceptance. Kinetics of donor cell trafficking and accumulation in pediatric allograft recipients are largely unknown. In this study, we implemented SNPs of the HVRs I and II of mitochondrial DNA to serve as molecular genetic markers to detect donor-specific cell chimerism after pediatric renal transplantation. Serial dilution of artificial chimeric DNA samples showed a linear correlation coefficient of R > 0.98 and a detection sensitivity of 0.01% with high reproducibility. Longitudinal semiquantitative analysis of donor-specific SNPs was then performed in peripheral blood mononuclear cells samples up to two yr post-transplant. Quantity of donor-specific cell chimerism in peripheral blood was highest in the early post-transplant period reaching values of ~10% after liver-kidney and 2.8% after renal transplantation. From one wk after transplantation, renal transplant patients exhibited an amount of donor-specific mtDNA ranging from 0.01% to 0.1%. We developed a highly accurate, sensitive, and rapid real-time quantitative PCR method using sequence-specific primers and fluorescent hydrolysis probes for the detection of at least 0.01% donor-specific cells in the recipient's peripheral blood after renal transplantation.
    Pediatric Transplantation 10/2011; 15(8):809-18. · 1.50 Impact Factor